While some insurers are cutting rebates for Ozempic and similar weight-loss drugs, others are waiting to see whether the long-term benefits outweigh the risks.
Article
Premium
0.25CIP Points
Weight loss drugs a dilemma for insurers amid celebrity hype
While some insurers are cutting rebates for Ozempic and similar weight-loss drugs, others are waiting to see whether the long-term benefits outweigh the risks.
Comments
Remove Comment
Are you sure you want to delete your comment?
This cannot be undone.